Tag Archives: NASDAQ:MRNS
Analysts Have Conflicting Sentiments on These Healthcare Companies: Marinus (NASDAQ: MRNS), Abiomed (NASDAQ: ABMD) and Albireo Pharma (NASDAQ: ALBO)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Marinus (MRNS – Research Report), Abiomed (ABMD – Research Report) and Albireo Pharma (ALBO – Research Report). Marinus (MRNS) Ladenburg Thalmann & Co. analyst Michael
Marinus (MRNS) Receives a Buy from H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Marinus (MRNS – Research Report) yesterday and set a price target of $6.00. The company’s shares closed last Monday at $2.51. According to TipRanks.com, Tsao is a 5-star analyst with
Analysts Offer Insights on Healthcare Companies: Marinus (NASDAQ: MRNS) and Siemens Healthineers AG (Other OTC: SEMHF)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Marinus (MRNS – Research Report) and Siemens Healthineers AG (SEMHF – Research Report). Marinus (MRNS) In a report released today, Douglas Tsao from
Ladenburg Thalmann & Co. Maintains a Buy Rating on Marinus (MRNS)
In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Marinus (MRNS – Research Report), with a price target of $5.00. The company’s shares closed last Tuesday at $2.03. According to TipRanks.com, Higgins
Oppenheimer Sticks to Their Buy Rating for Marinus (MRNS)
Oppenheimer analyst Jay Olson maintained a Buy rating on Marinus (MRNS – Research Report) yesterday and set a price target of $6.00. The company’s shares closed last Monday at $2.13. According to TipRanks.com, Olson is ranked 0 out of 5
Marinus (MRNS) Received its Third Buy in a Row
After Ladenburg Thalmann & Co. and Oppenheimer gave Marinus (NASDAQ: MRNS) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Douglas Tsao reiterated a Buy rating on Marinus today and set a price
